You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim and Click Therapeutics join hands for CT-155, digital therapeutic for schizophrenia expresspharma
September 14, 2020
Boehringer Ingelheim and Click Therapeutics announced they have entered into a collaboration for the development and commercialisation of a prescription-based digital therapeutic.
BiomX collaborates with Boehringer Ingelheim for microbiome-based biomarkers for IBD expresspharma
September 03, 2020
The terms of the collaboration also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered utilising the XMarker platform.
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults expresspharma
August 31, 2020
Boehringer Ingelheim announced the full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes.
Boehringer Ingelheim Enrolls First Patient to Evaluate nintedanib for Pediatric Fibrosing ILD americanpharmaceuticalreview
August 17, 2020
Boehringer Ingelheim announced the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing ...
Boehringer Ingelheim expands animal health portfolio in India market with two new drugs launches expresspharma
August 03, 2020
Boehringer Ingelheim announced the launch of two new products in their animal healthcare portfolio for the India market.
Cipla and Boehringer Ingelheim to co-market three oral anti-diabetic drugs expresspharma
June 30, 2020
The two companies will help co-market three anti-diabetic drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
Boehringer Ingelheim Appoints New U.S. CEO contractpharma
June 16, 2020
Jean-Michel Boers to succeed Dr. Wolfgang Baiker, who is retiring after 31 years.
New consortium EUbOPEN will provide tools to unlock disease biology worldpharmanews
June 10, 2020
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete.
Boehringer Ingelheim acquires Northern Biologics’ preclinical cancer antibody pipeline expresspharma
May 18, 2020
The acquisition provides assets targeting tumour stroma and myeloid cells.
Boehringer Ingelheim gets EC approval for nintedanib to treat SSc-ILD pharmaceutical-business-review
April 26, 2020
Boehringer Ingelheim has secured approval from the European Commission (EC) for its nintedanib to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adult patients.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page